FY2030 Earnings Estimate for JSPR Issued By HC Wainwright

Jasper Therapeutics, Inc. (NASDAQ:JSPR) – Stock analysts at HC Wainwright issued their FY2030 EPS estimates for shares of Jasper Therapeutics in a research report issued to clients and investors on Tuesday, March 31st. HC Wainwright analyst E. Bodnar expects that the company will post earnings of ($0.75) per share for the year. The consensus estimate for Jasper Therapeutics’ current full-year earnings is ($4.47) per share.

Several other research analysts also recently commented on JSPR. UBS Group began coverage on Jasper Therapeutics in a report on Monday, March 23rd. They set a “neutral” rating on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of Jasper Therapeutics in a report on Thursday, January 22nd. Finally, Rodman & Renshaw assumed coverage on Jasper Therapeutics in a research report on Tuesday, January 13th. They set a “buy” rating and a $17.00 price target on the stock. Six analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $19.88.

Jasper Therapeutics Stock Performance

Shares of NASDAQ JSPR opened at $0.88 on Wednesday. The firm has a market capitalization of $24.52 million, a price-to-earnings ratio of -0.19 and a beta of 3.08. The stock has a 50 day moving average price of $1.32 and a 200 day moving average price of $1.76. Jasper Therapeutics has a 52-week low of $0.81 and a 52-week high of $7.19.

Jasper Therapeutics (NASDAQ:JSPR) last issued its earnings results on Monday, March 30th. The company reported ($0.32) EPS for the quarter, topping analysts’ consensus estimates of ($0.79) by $0.47.

Hedge Funds Weigh In On Jasper Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of JSPR. Engineers Gate Manager LP bought a new position in shares of Jasper Therapeutics during the fourth quarter valued at approximately $26,000. Panagora Asset Management Inc. bought a new position in Jasper Therapeutics in the fourth quarter worth approximately $35,000. Acadian Asset Management LLC bought a new position in Jasper Therapeutics in the first quarter worth approximately $46,000. Voleon Capital Management LP purchased a new stake in Jasper Therapeutics during the third quarter worth $50,000. Finally, Marex Group plc bought a new stake in Jasper Therapeutics during the 2nd quarter valued at $74,000. 79.85% of the stock is currently owned by institutional investors.

About Jasper Therapeutics

Jasper Therapeutics, Inc (NASDAQ: JSPR) is a clinical-stage biopharmaceutical company focused on translating advances in immunobiology into therapies for serious and rare diseases with unmet medical needs. The company’s research and development efforts center on engineered biologics and cell-based approaches designed to address complications in hematologic conditions and improve outcomes in transplant medicine.

Central to Jasper’s pipeline is JSP191, a monoclonal antibody targeting the CD117 receptor, which is being evaluated to enhance donor hematopoietic stem cell engraftment in patients undergoing stem cell transplantation.